HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

AbstractOBJECTIVES:
Metronidazole, a mainstay treatment for Clostridium difficile infection (CDI), is often ineffective for severe CDI. Whilst this is thought to arise from suboptimal levels of metronidazole in the colon due to rapid absorption, empirical validation is lacking. In contrast, reutericyclin, an antibacterial tetramic acid from Lactobacillus reuteri, concentrates in the gastrointestinal tract. In this study, we modified metronidazole with reutericyclin's tetramic acid motif to obtain non-absorbed compounds, enabling assessment of the impact of pharmacokinetics on treatment outcomes.
METHODS:
A series of metronidazole-bearing tetramic acid substituents were synthesized and evaluated in terms of anti-C. difficile activities, gastric permeability, in vivo pharmacokinetics, efficacy in the hamster model of CDI and mode of action.
RESULTS:
Most compounds were absorbed less than metronidazole in cell-based Caco-2 permeability assays. In hamsters, lead compounds compartmentalized in the colon rather than the bloodstream with negligible levels detected in the blood, in direct contrast with metronidazole, which was rapidly absorbed into the blood and was undetectable in caecum. Accordingly, four leads were more efficacious (Pā€Š<ā€Š0.05) than metronidazole in C. difficile-infected animals. Improved efficacy was not due to an alternative mode of action, as the leads retained the mode of action of metronidazole.
CONCLUSIONS:
This study provides the clearest empirical evidence that the high absorption of metronidazole lowers treatment outcomes for CDI and suggests a role for the tetramic acid motif for colon-specific drug delivery. This approach also has the potential to lower systemic toxicity and drug interactions of nitroheterocyclic drugs for treating gastrointestine-specific diseases.
AuthorsPhilip T Cherian, Xiaoqian Wu, Lei Yang, Jerrod S Scarborough, Aman P Singh, Zahidul A Alam, Richard E Lee, Julian G Hurdle
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 70 Issue 11 Pg. 3061-9 (Nov 2015) ISSN: 1460-2091 [Electronic] England
PMID26286574 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: [email protected].
Chemical References
  • Anti-Bacterial Agents
  • Pyrrolidinones
  • reutericyclin
  • Metronidazole
  • tetramic acid
  • Tenuazonic Acid
Topics
  • Animals
  • Anti-Bacterial Agents (administration & dosage, chemistry, pharmacokinetics)
  • Clostridioides difficile (drug effects)
  • Clostridium Infections (drug therapy)
  • Colon (chemistry)
  • Disease Models, Animal
  • Male
  • Mesocricetus
  • Metronidazole (administration & dosage, chemistry, pharmacokinetics)
  • Pyrrolidinones (chemistry, pharmacokinetics)
  • Tenuazonic Acid (analogs & derivatives, chemistry, pharmacokinetics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: